PA
GILD icon

Prossimo Advisors’s Gilead Sciences GILD Stock Holding History

Prossimo Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,141
Closed -$237K – 62
2025
Q2 		$237K Buy
+2,141
New +$228K 0.19% 117
2023
Q3 		– Sell
-8,910
Closed -$687K – 77
2023
Q2 		$687K Buy
+8,910
New +$711K 0.66% 43

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Prossimo Advisors's GILD Position: Q3 2025 in Review

Prossimo Advisors sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 2,141 shares — an estimated $237K sold.

Prossimo Advisors first reported a position in GILD in Q2 2023 and held it in 2 quarters. The position peaked at $687K in Q2 2023. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

  • Prossimo Advisors reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
  • Prossimo Advisors sold 2,141 Gilead Sciences shares in Q3 2025, an estimated $237K.
  • Prossimo Advisors first reported a position in Gilead Sciences in Q2 2023 and held it in 2 quarters.
  • Prossimo Advisors's Gilead Sciences position peaked at $687K in Q2 2023.
  • 2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on Prossimo Advisors's 13F filing for Q3 2025, filed 28 Oct 2025.